Jupiter Life Line Hospitals Limited | Globe Capital Market LTD.
Jupiter Life Line Hospitals Limited
Price Band
₹695 to ₹735 per share
IPO Issue Period
Sep 6, 2023 to Sep 8, 2023
Issue Size
₹869.08 Cr
Face value
₹10 per share
Fresh issue
₹542.00 Cr
Offer for sale
₹327.08 Cr
Minimum Shares for Retail
Listing on
Issue Type
Book Building
Registrar to the Issue
Kfin Technologies Limited
Tentative Listing Date
Monday, September 18, 2023

ICICI Securities Limited
Nuvama Wealth Management Limited
Jm Financial Limited

Jupiter Life Line Hospitals Limited is among the key multi-specialty tertiary and quaternary healthcare providers in the Mumbai Metropolitan Area (MMR) and western region of India with a total bed capacity of 1,194 hospital beds across three hospitals as of March 31, 2023. It has been operating as a corporate quaternary care healthcare service provider in the western regions of India and currently operates three hospitals under the “Jupiter” brand in Thane, Pune, and Indore.

According to the CRISIL Report, the company’s Thane and Indore hospitals are amongst the few hospitals in the western region of India to provide neuro-rehabilitation services through a dedicated robotic and computer-assisted neuro-rehabilitation center. Additionally, it operates one of the few multi-organ transplant centers in Thane. All the hospitals in Thane, Pune, and Indore have been certified by the National Accreditation Board for Hospitals & Healthcare Providers (NABH) and have been accredited in the field of medical testing by the National Accreditation Board for Testing and Calibration Laboratories (NABL). There are 1,306 doctors including specialists, physicians and surgeons, as of March 31, 2023. It is also currently in the process of developing a multi-specialty hospital in Dombivli, Maharashtra, which is designed to accommodate over 500 beds and has commenced construction in April 2023

The company’s inpatient and outpatient revenue is diversified across hospitals with Thane, Pune, and Indore hospitals accounting for 54.18%, 34.03%, and 11.79%, respectively, of the revenue from operations in Fiscal 2023.

For year/ period ended ( in Cr.)

H1FY23 FY22 FY21
Total Revenue 902.96 737.14 490.26
Profit After Tax 72.90 51.12 (2.29)
EPS 13.95 10.05 (0.45)
OPM (%) 14.25% 10.46% 0.31%
PATM (%) 8.07% 6.93% -0.47%


  • Key multi-specialty tertiary and quaternary healthcare provider with a track record of over 15 years, strong brand recognition and clinical expertise.
  • ‘All-hub-no-spoke’ model with focus on quality patient care supported by modern infrastructure and technological capabilities.
  • Ability to attract and retain skilled and experienced healthcare professionals.
  • Track-record of operational and financial performance with a diversified revenue mix.
  • Experienced and qualified professional management team with a focus on environmental, social and governance initiatives.
  • Repayment/pre-payment, in full or part, of borrowings availed from banks by the company and Material Subsidiary; &
  • General corporate purposes.

The Company is a known chain of Hospitals in the MMR regions and gaining preference due to its high-tech and advanced healthcare services with ultramodern diagnostic services. Investors may consider investment for the medium to long term in this issue.

Be a Part of IPO Success Stories!

Never Miss IPO Investment